Simulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients

Patent metadata

Field	Value
Publication number	US-10169544-B2
Application number	US-201414902731-A
Country	US
Kind code	B2
Filing date	Jul 3, 2014
Priority date	Jul 3, 2013
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

A simulator for in-silico testing of Type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose G and insulin /, with glucose fluxes, i.e. endogenous glucose production (EGP), glucose rate of appearance (Ra), glucose utilization by the tissues (U), renal extraction (E), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (SC) and insulin degradation (D). A module is also included to describe counter-regulation, i.e. glucagon kinetics, secretion and action. A glucagon subcutaneous absorption model enables simulation of dual hormone control.

First claim

What is claimed is:

1. An electronic system that simulates a glucose-insulin metabolic system of a T1DM subject, comprising:
an electronic subsystem configured to model dynamic glucose concentration in the T1DM subject, including an electronic module configured to model glucagon action on endogenous glucose production (EGP(t)),
an electronic module configured to model meal glucose rate of appearance (Ra(t)),
an electronic module configured to model insulin-dependent glucose utilization (U id (t)), according to following equation:

U
id

⁡

(
t
)

=

[

V

m
⁢

⁢
0

+

V
mx

·

X
⁡

(
t
)

·

(

1
+

r
1

·
risk

)

]

·

G
t

⁡

(
t
)

K

m
⁢

⁢
0

+

G
t

⁡

(
t
)

where G t (t) is an amount of glucose in tissue, X(t) is insulin action on glucose utilization and [V m0 , V mx , K m0 , p 2U ] are model parameters, where V m0 governs amplitude of insulin action on glucuose utilization at basal steady state, V mx governs amplitude of insulin action on glucuose utilization, K m0 governs glucose control on glucose utilization, p 2U accounts for delay between insulin signal and insulin action on glucose utilization, and

risk
=

{

0

if
⁢

⁢
G

≥

G
b

10
·

[

f
⁡

(
G
)

]

2

if
⁢

⁢

G
th

≤
G
<

G
b

10
·

[

f
⁡

(

G
th

)

]

2

if
⁢

⁢
G

<

G
th

with G being total glucose, G b being patient basal glucose, G th a hypoglycemic threshold, which is set at 60 mg/d1, and risk is a measure of risk of hypoglycemia,

f
⁡

(
G
)

=

log
⁡

(

G

G
b

Assignees

• Univ Virginia Patent Foundation

Inventors

• Breton Marc D
• Kovatchev Boris P
• Dalla Man Chiara
• Cobelli Claudio
• Micheletto Francesco

Classifications

• G16H50/50

  for simulation or modelling of medical disorders · CPC title

• G16C20/10 Primary

  Analysis or design of chemical reactions, syntheses or processes · CPC title

• G06F19/00

  Physics · mapped topic

• G06F19/702 Primary

  Physics · mapped topic

• G16Z99/00

  Subject matter not provided for in other main groups of this subclass · CPC title